María Teresa Arias Loste-rekin lankidetzan egindako argitalpenak (2)

2023

  1. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 2, pp. 406-414.e7

2022

  1. Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy

    Therapeutic Advances in Gastroenterology, Vol. 15